Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Operating Expenses (2019 - 2025)

aTYR PHARMA's Operating Expenses history spans 7 years, with the latest figure at -$66.5 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 7708.1% year-over-year to -$66.5 million; the TTM value through Dec 2025 reached -$20.2 million, down 162.15%, while the annual FY2025 figure was -$3.5 million, 9.97% up from the prior year.
  • Operating Expenses reached -$66.5 million in Q4 2025 per ATYR's latest filing, down from $26.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $26.9 million in Q3 2025 to a low of -$66.5 million in Q4 2025.
  • Average Operating Expenses over 5 years is $7.9 million, with a median of $12.7 million recorded in 2022.
  • The largest YoY upside for Operating Expenses was 3153.85% in 2025 against a maximum downside of 7708.1% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $8.6 million in 2021, then soared by 112.22% to $18.3 million in 2022, then decreased by 12.96% to $16.0 million in 2023, then plummeted by 105.34% to -$852000.0 in 2024, then plummeted by 7708.1% to -$66.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Operating Expenses are -$66.5 million (Q4 2025), $26.9 million (Q3 2025), and $20.3 million (Q2 2025).